ArticleJournal of medical case reports2025
Cold versus warm autoimmune hemolytic anemia in diffuse large B cell lymphoma: pathogenic and therapeutic implications: a case series.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Rare Presentation of Mixed Warm and Cold Autoimmune Hemolytic Anemia.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAutoimmune hemolytic anemia-associated diffuse large B cell lymphoma is rare, with distinct pathogenic mechanisms and therapeutic responses in cold agglutinin syndrome (CAS) and warm autoimmune hemolytic anemia subtypes poorly characterized. This report highlights two novel cases demonstrating subtype-specific molecular drivers and treatment outcomes, underscoring the necessity for precision management. CASE PRESENTATION: Two patients presented with autoimmune hemolytic anemia: a 29-year-old Han male with cold agglutinin syndrome and a 37-year-old Han female with warm autoimmune hemolytic anemia who had 5-year history of symptoms. Both patients were diagnosed with nongerminal center B cell (nonGCB) diffuse large B cell lymphoma. The male cold agglutinin syndrome-diffuse large B cell lymphoma patient exhibited monoclonal IgM-κ-driven complement-mediated intravascular hemolysis via a direct "tumor-antibody-erythrocyte" axis, accompanied by BCL6 amplification, and achieved rapid remission with rituximab monotherapy. The female warm autoimmune hemolytic anemia-diffuse large B cell lymphoma patient demonstrated polyclonal IgG-mediated macrophage erythrophagocytosis (via the JAK-STAT pathway) and BCL2/BCL6 co-amplification, requiring R-CHOP chemotherapy to control refractory hemolysis.
conclusionThese cases reveal distinct molecular mechanisms (BCL6 versus BCL2/BCL6 amplification) and therapeutic vulnerabilities in autoimmune hemolytic anemia-diffuse large B cell lymphoma subtypes, requiring subtype-specific treatment. A screening triad-refractory hemolysis, cytopenia, and lymphatic/splenic involvement-enables early lymphoma detection. Molecular profiling may guide precision therapy, improving outcomes in this rare disease spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.